Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual InhibitorsNoel D. D’Angelo, Mark H. Norman, Douglas A. Whittington et al.|Journal of Medicinal Chemistry|2011Cited by 120
Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline DerivativesNobuko Nishimura, Mark H. Norman, Aaron Siegmund et al.|Journal of Medicinal Chemistry|2011Cited by 60
Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-KinasesAdrian L. Smith, Mark H. Norman, Noel D. D’Angelo et al.|Journal of Medicinal Chemistry|2012Cited by 50
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511Mark H. Norman, Paul E. Hughes, Kristin L. Andrews et al.|Journal of Medicinal Chemistry|2012Cited by 50
Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic StabilityMarkian M. Stec, Mark H. Norman, Kristin L. Andrews et al.|Journal of Medicinal Chemistry|2011Cited by 44